Selective estrogen receptor modulators.
Kearney
C E
CE
Centre for Metabolic Bone Disease, University of Hull, Royal Hull Hospitals NHS Trust, Hull, UK.
Purdie
D W
DW
D000368:Aged; D000818:Animals; D001943:Breast Neoplasms / Q000453:epidemiology / Q000209:etiology; D004965:Estrogen Antagonists / Q000008:administration & dosage / Q000627:therapeutic use; D015914:Estrogen Replacement Therapy / Q000009:adverse effects; D005260:Female; D006801:Humans; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000517:prevention & control; D020849:Raloxifene Hydrochloride / Q000008:administration & dosage / Q000627:therapeutic use; D011960:Receptors, Estrogen / Q000737:chemistry / Q000502:physiology; D020845:Selective Estrogen Receptor Modulators; D013629:Tamoxifen / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use
D004965:Estrogen Antagonists; D011960:Receptors, Estrogen; D020845:Selective Estrogen Receptor Modulators; D013629:Tamoxifen; D020849:Raloxifene Hydrochloride